Christine M Durand1, Mary G Bowring1, Alvin G Thomas1, Lauren M Kucirka1, Allan B Massie2, Andrew Cameron1, Niraj M Desai1, Mark Sulkowski1, Dorry L Segev3. 1. Johns Hopkins University School of Medicine, Baltimore, Maryland (C.M.D., M.G.B., A.G.T., L.M.K., A.C., N.M.D., M.S.). 2. Johns Hopkins University School of Medicine and Johns Hopkins School of Public Health, Baltimore, Maryland (A.B.M.). 3. Johns Hopkins University School of Medicine and Johns Hopkins School of Public Health, Baltimore, Maryland, and Scientific Registry of Transplant Recipients, Minneapolis, Minnesota (D.L.S.).
Abstract
Background: The epidemic of drug overdose deaths in the United States has led to an increase in organ donors. Objective: To characterize donors who died of overdose and to analyze outcomes among transplant recipients. Design: Prospective observational cohort study. Setting: Scientific Registry of Transplant Recipients, 1 January 2000 to 1 September 2017. Participants: 138 565 deceased donors; 337 934 transplant recipients at 297 transplant centers. Measurements: The primary exposure was donor mechanism of death (overdose-death donor [ODD], trauma-death donor [TDD], or medical-death donor [MDD]). Patient and graft survival and organ discard (organ recovered but not transplanted) were compared using propensity score-weighted standardized risk differences (sRDs). Results: A total of 7313 ODDs and 19 897 ODD transplants (10 347 kidneys, 5707 livers, 2471 hearts, and 1372 lungs) were identified. Overdose-death donors accounted for 1.1% of donors in 2000 and 13.4% in 2017. They were more likely to be white (85.1%), aged 21 to 40 years (66.3%), infected with hepatitis C virus (HCV) (18.3%), and increased-infectious risk donors (IRDs) (56.4%). Standardized 5-year patient survival was similar for ODD organ recipients compared with TDD organ recipients (sRDs ranged from 3.1% lower to 3.9% higher survival) and MDD organ recipients (sRDs ranged from 2.1% to 5.2% higher survival). Standardized 5-year graft survival was similar between ODD and TDD grafts (minimal difference for kidneys and lungs, marginally lower [sRD, -3.2%] for livers, and marginally higher [sRD, 1.9%] for hearts). Kidney discard was higher for ODDs than TDDs (sRD, 5.2%) or MDDs (sRD, 1.5%); standardization for HCV and IRD status attenuated this difference. Limitation: Inability to distinguish between opioid and nonopioid overdoses. Conclusion: In the United States, transplantation with ODD organs has increased dramatically, with noninferior outcomes in transplant recipients. Concerns about IRD behaviors and hepatitis C among donors lead to excess discard that should be minimized given the current organ shortage. Primary Funding Source: National Institutes of Health.
Background: The epidemic of drug overdose deaths in the United States has led to an increase in organ donors. Objective: To characterize donors who died of overdose and to analyze outcomes among transplant recipients. Design: Prospective observational cohort study. Setting: Scientific Registry of Transplant Recipients, 1 January 2000 to 1 September 2017. Participants: 138 565 deceased donors; 337 934 transplant recipients at 297 transplant centers. Measurements: The primary exposure was donor mechanism of death (overdose-deathdonor [ODD], trauma-deathdonor [TDD], or medical-death donor [MDD]). Patient and graft survival and organ discard (organ recovered but not transplanted) were compared using propensity score-weighted standardized risk differences (sRDs). Results: A total of 7313 ODDs and 19 897 ODD transplants (10 347 kidneys, 5707 livers, 2471 hearts, and 1372 lungs) were identified. Overdose-death donors accounted for 1.1% of donors in 2000 and 13.4% in 2017. They were more likely to be white (85.1%), aged 21 to 40 years (66.3%), infected with hepatitis C virus (HCV) (18.3%), and increased-infectious risk donors (IRDs) (56.4%). Standardized 5-year patient survival was similar for ODD organ recipients compared with TDD organ recipients (sRDs ranged from 3.1% lower to 3.9% higher survival) and MDD organ recipients (sRDs ranged from 2.1% to 5.2% higher survival). Standardized 5-year graft survival was similar between ODD and TDD grafts (minimal difference for kidneys and lungs, marginally lower [sRD, -3.2%] for livers, and marginally higher [sRD, 1.9%] for hearts). Kidney discard was higher for ODDs than TDDs (sRD, 5.2%) or MDDs (sRD, 1.5%); standardization for HCV and IRD status attenuated this difference. Limitation: Inability to distinguish between opioid and nonopioid overdoses. Conclusion: In the United States, transplantation with ODD organs has increased dramatically, with noninferior outcomes in transplant recipients. Concerns about IRD behaviors and hepatitis C among donors lead to excess discard that should be minimized given the current organ shortage. Primary Funding Source: National Institutes of Health.
Authors: Wesley J Marrero; Abhijit S Naik; John J Friedewald; Yongcai Xu; David W Hutton; Mariel S Lavieri; Neehar D Parikh Journal: Transplantation Date: 2017-07 Impact factor: 4.939
Authors: Varun Saxena; Vandana Khungar; Elizabeth C Verna; Josh Levitsky; Robert S Brown; Mohamed A Hassan; Mark S Sulkowski; Jacqueline G O'Leary; Farrukh Koraishy; Joseph S Galati; Alexander A Kuo; Monika Vainorius; Lucy Akushevich; David R Nelson; Michael W Fried; Norah Terrault; K Rajender Reddy Journal: Hepatology Date: 2017-09-04 Impact factor: 17.425
Authors: L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev Journal: Am J Transplant Date: 2011-03-14 Impact factor: 8.086
Authors: M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand Journal: Am J Transplant Date: 2016-08-24 Impact factor: 8.086
Authors: Muhammed A Gok; Ajay Gupta; Peter Olschewski; Aftab Bhatti; Brian K Shenton; Helen Robertson; Naeem Soomro; David Talbot Journal: Clin Transplant Date: 2004-10 Impact factor: 2.863
Authors: Mary G Bowring; Kyle R Jackson; Heather Wasik; Alicia Neu; Jacqueline Garonzik-Wang; Christine Durand; Niraj Desai; Allan B Massie; Dorry L Segev Journal: Transplantation Date: 2019-12 Impact factor: 4.939
Authors: Kerollos Nashat Wanis; Arin L Madenci; Mary Katherine Dokus; Mark S Orloff; Mark A Levstik; Roberto Hernandez-Alejandro; Miguel A Hernán Journal: Eur J Epidemiol Date: 2019-01-23 Impact factor: 8.082
Authors: George Cholankeril; Andrew A Li; Brittany B Dennis; Alice E Toll; Donghee Kim; C Andrew Bonham; Satheesh Nair; Aijaz Ahmed Journal: Clin Gastroenterol Hepatol Date: 2018-09-27 Impact factor: 11.382
Authors: Ricardo M La Hoz; Burhaneddin Sandıkçı; Venkatesh K Ariyamuthu; Bekir Tanriover Journal: Am J Transplant Date: 2019-08-07 Impact factor: 8.086
Authors: Jordan J Feld; Marcelo Cypel; Deepali Kumar; Harel Dahari; Rafaela Vanin Pinto Ribeiro; Nikki Marks; Nellie Kamkar; Ilona Bahinskaya; Fernanda Q Onofrio; Mohamed A Zahoor; Orlando Cerrochi; Kathryn Tinckam; S Joseph Kim; Jeffrey Schiff; Trevor W Reichman; Michael McDonald; Carolina Alba; Thomas K Waddell; Gonzalo Sapisochin; Markus Selzner; Shaf Keshavjee; Harry L A Janssen; Bettina E Hansen; Lianne G Singer; Atul Humar Journal: Lancet Gastroenterol Hepatol Date: 2020-05-06
Authors: Peng-Sheng Ting; James Peter Hamilton; Ahmet Gurakar; Nathalie H Urrunaga; Michelle Ma; Jaime Glorioso; Elizabeth King; Lindsey P Toman; Russell Wesson; Jacqueline Garonzik-Wang; Shane Ottmann; Benjamin Philosophe; Mark Sulkowski; Andrew M Cameron; Christine M Durand; Po-Hung Chen Journal: Transpl Infect Dis Date: 2019-10-30 Impact factor: 2.228